PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

| NAME | : Mr. BALJEET SINGH | | | | |
|----------------|----------------------------|---|------------------------|--|--|
| AGE/ GENDER | : 58 YRS/MALE | P | ATIENT ID | : 1711597 | |
| COLLECTED BY | : | R | EG. NO./LAB NO. | : 122412300001 | |
| REFERRED BY | : | REGISTRATION DATE : 30/Dec/2024 08 | | : 30/Dec/2024 08:28 AM | |
| BARCODE NO. | | | COLLECTION DATE | : 30/Dec/2024 09:00AM : 30/Dec/2024 10:30AM | |
| CLIENT CODE. | | | REPORTING DATE | | |
| CLIENT ADDRESS | : NASIRPUR, HISSAR ROAD, A | MBALA CITY - HAR | YANA | | |
| | | | | | |
| Test Name | | Value | Unit | Biological Reference interva | |
| Test Name | CLINI | | Unit RY/BIOCHEMIST | | |
| Test Name | CLINI | CAL CHEMIST | | | |

A fasting plasma glucose level below 100 mg/dl is considered normal.
A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood test (after consumption of 75 gms of glucose) is recommended for all such patients.
A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)**



PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

| NAME | : Mr. BALJEET SINGH | | | | |
|---|-----------------------------------|---------------------|--------------------------|---|--|
| AGE/ GENDER | : 58 YRS/MALE | | PATIENT ID | : 1711597 | |
| COLLECTED BY | : | | REG. NO./LAB NO. | : 122412300001 : 30/Dec/2024 08:28 AM | |
| REFERRED BY | : | | REGISTRATION DATE | | |
| BARCODE NO. | : 12506332 | | COLLECTION DATE | : 30/Dec/2024 09:00AM | |
| CLIENT CODE. | : P.K.R JAIN HEALTHCARE INS | TITUTE | REPORTING DATE | : 30/Dec/2024 10:30AM | |
| CLIENT ADDRESS | : NASIRPUR, HISSAR ROAD, AI | | | | |
| Test Name | | Value | Unit | Biological Reference interval | |
| | | LIPID PR | OFILE : BASIC | | |
| CHOLESTEROL TO by CHOLESTEROL O> | | 214.79 ^H | mg/dL | OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0 | |
| TRIGLYCERIDES: S by GLYCEROL PHOSF | ERUM PHATE OXIDASE (ENZYMATIC) | 100.17 | mg/dL | OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0 | |
| HDL CHOLESTERO by SELECTIVE INHIBIT | L (DIRECT): SERUM 70N | 55.02 | mg/dL | LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 60.0 HIGH HDL: > OR = 60.0 | |
| LDL CHOLESTERO by CALCULATED, SPE | | 139.74 ^H | mg/dL | OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0 | |
| NON HDL CHOLES by CALCULATED, SPE | | 159.77 ^H | mg/dL | OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0 | |
| VLDL CHOLESTER(| | 20.03 | mg/dL | 0.00 - 45.00 | |
| TOTAL LIPIDS: SER by CALCULATED, SPE | RUM | 529.75 | mg/dL | 350.00 - 700.00 | |
| CHOLESTEROL/HI by CALCULATED, SPE | | 3.9 | RATIO | LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 | |



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

NOT VALID FOR MEDICO LEGAL PURPOSE

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)**



PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

| NAME | : Mr. BALJEET SINGH | | |
|--------------------|--|--------------------------|------------------------|
| AGE/ GENDER | : 58 YRS/MALE | PATIENT ID | : 1711597 |
| COLLECTED BY | : | REG. NO./LAB NO. | : 122412300001 |
| REFERRED BY | : | REGISTRATION DATE | : 30/Dec/2024 08:28 AM |
| BARCODE NO. | : 12506332 | COLLECTION DATE | : 30/Dec/2024 09:00AM |
| CLIENT CODE. | : P.K.R JAIN HEALTHCARE INSTITUTE | REPORTING DATE | : 30/Dec/2024 10:30AM |
| CLIENT ADDRESS | : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA | | |

| Test Name | Value | Unit | Biological Reference interval |
|--|-------------------|-------|---|
| LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY | 2.54 | RATIO | LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0 |
| TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY | 1.82 ^L | RATIO | 3.00 - 5.00 |

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

 Low hole to consider a structure of the process by which cholesterol is eliminated from peripheral tissues.
NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL.

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

*** End Of Report





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)**

